Ultra-hypofractionated Radiotherapy in Breast Cancer: Clinical Outcomes, Cost-Effectiveness, and Implementation Considerations
-(1).jpg)
Ultrahypofractionated radiation therapy (UHF-RT) is an emerging approach in breast cancer treatment, delivering effective therapy in one week compared to conventional three-week schedules. Supported by the FAST-Forward trials and its 2025 nodal sub-study, this innovation enhances patient convenience, reduces healthcare resource use, and is increasingly shaping modern radiotherapy practice worldwide.
Introduction
Radiation therapy (RT) has been an essential component of breast cancer management for decades. After breast-conserving surgery, adjuvant radiation substantially reduces recurrence risk and improves survival. Meta-analyses have shown that postoperative RT lowers any breast cancer recurrence by about 50% and breast cancer-specific mortality by roughly one-sixth [1].
The benefits of RT are well established, but treatment methods have continued to evolve. The move from five-week to five-day courses reflects ongoing technological progress and an evidence-based approach to improving efficiency, patient experience, and sustainability.
From Conventional to Moderate Hypofractionation
For much of the late twentieth century, standard postoperative breast RT consisted of 23-28 fractions of 1.8-2.3 Gy each, delivered over five weeks. This conventional approach was originally developed to minimise late toxicity, guided by radiobiological models that favoured smaller daily doses. While effective, its prolonged duration created challenges for many patients, particularly those living far from treatment centres, and placed considerable pressure on RT resources.
From the mid-1990s to the early 2000s, a series of large randomised trials explored whether slightly higher doses per fraction could achieve equivalent tumour control with fewer treatment sessions. Landmark studies from the United Kingdom (UK) and Canada demonstrated that moderate hypofractionation (MHF), typically 40–42.5 Gy in 15–16 fractions over three weeks, was non-inferior to conventional regimens in terms of efficacy, cosmetic outcomes, and late normal-tissue effects [2-6].
As a result, by the mid-2010s, MHF became the standard of care for most women receiving postoperative breast RT. The success of these studies provided a foundation for exploring even shorter schedules.
Development of Ultra-hypofractionation
The next major step in this evolution was ultra-hypofractionated RT (UHF-RT), which delivers the full course of treatment in five fractions over one week. The aim was to determine whether treatment time could be reduced even further without compromising tumour control or safety.
This became feasible thanks to technological advances such as three-dimensional planning, image-guided delivery, and improved dose homogeneity. The pivotal FAST-Forward trial, conducted across multiple centres in the UK, directly compared a one-week regimen (26 Gy in five fractions) with the standard three-week schedule. The trial demonstrated that the one-week course was non-inferior for local tumour control, with similar rates of normal-tissue effects and cosmetic outcomes. Long-term follow-up confirmed durable disease control and no increase in late toxicity [7].
Building on this evidence, the ESTRO–ACROP consensus published in The Lancet in 2022 strongly endorses UHF-RT as a safe and effective option for most patients with early-stage breast cancer. ESTRO recommends its use for whole-breast irradiation (WBI) after breast- conserving surgery and notes that it may also be appropriate for the chest wall and regional nodes in selected patients [8].
Further reassurance came in May 2025, when the publication of the FAST-Forward nodal sub-study confirmed that including regional lymph nodes in the one-week regimen resulted in comparable arm and shoulder morbidity to the three-week schedule, with no brachial plexus complications reported [9].
Prof. Angel Montero and his colleagues from Spain analysed acute skin toxicity in a cohort of 383 patients with early breast cancer who underwent UHF WBI (26 Gy in 5 fractions) with a simultaneous integrated boost (SIB) to the tumour bed (29 Gy in 5 fractions, or 30–31 Gy for patients with close margins). Their study demonstrated that UHF WBI + SIB delivered over one week is feasible and well tolerated, with low rates of acute skin toxicity and minimal breast oedema [10].
Clinical Benefits of the Five-Fraction Schedule
The five-fraction regimen offers multiple advantages for both patients and healthcare systems. By completing RT in just one week, patients experience less disruption to their daily lives, and treatment becomes more accessible for those who live far from cancer centres.
Clinical trials have demonstrated that this shorter schedule provides comparable efficacy to longer regimens, with similar rates of local control and survival. Tolerability is also favourable, with recent prospective studies of one-week locoregional RT showing low rates of acute side effects, most of which are mild and manageable. Long-term results from the FAST-Forward trial and its nodal sub-study further confirm excellent tumour control without an increase in late toxicity.
From a health system perspective, the reduced treatment duration afforded by five-fraction regimens enables radiation oncology departments to treat a greater number of patients using existing infrastructure, thereby improving service efficiency and reducing waiting times. Economic evaluations conducted in Europe and North America have demonstrated substantial reductions in both direct healthcare costs and out-of-pocket expenses for patients, attributable to the decreased number of treatment sessions. Modelling studies further indicate that replacing conventional fractionation with hypofractionated whole-breast irradiation could lower departmental costs per patient by approximately 40%, while simultaneously increasing the proportion of patients able to access RT by up to 25% [11].
In the United Kingdom, model-based analyses provide additional support for the economic and health advantages of shorter regimens. One study compared five-fraction whole-breast irradiation (WB5F) and partial-breast irradiation (PB5F) with their respective fifteen-fraction counterparts. The analysis demonstrated that WB5F dominated the conventional fifteen- fraction whole-breast regimen, achieving both reduced costs, estimated at over £2,000 per patient, and modestly higher quality-adjusted life-years (QALYs). Among patients eligible for partial-breast irradiation, PB5F offered the lowest cost and highest expected QALYs, further highlighting the value of fraction reduction where clinically appropriate [12].
Collectively, these findings indicate that adopting evidence-based hypofractionated schedules not only preserves clinical efficacy but also delivers measurable economic benefits and potential improvements in patient outcomes. In low- and middle-income countries, where RT capacity is often limited, hypofractionated regimens have the potential to expand access, decrease patient burden, and optimise the utilisation of scarce healthcare resources.
Barriers to adoption
Despite strong clinical evidence supporting UHF-RT, its adoption in routine practice remains inconsistent. Multiple, interconnected factors contribute to this variability. Institutional policies, infrastructure, and reimbursement systems are critical determinants of practice, and global analyses have demonstrated that successful implementation depends on adequate equipment, well-trained staff, and the integration of updated clinical guidelines. In lower- and middle-income countries, limited treatment-planning capacity, fewer RT machines, and frequent machine downtime make delivering shorter regimens particularly challenging. Surveys of international clinicians further highlight that lack of experience and confidence is a major barrier to adoption [13].
Financial incentives also shape clinical practice. In many healthcare systems, reimbursement structures still reward longer treatment courses, which can discourage the use of shorter, evidence-based regimens. Safety concerns further contribute to hesitation, as some clinicians worry about higher rates of acute or late toxicity, despite consistent evidence from recent prospective studies and major clinical trials showing that UHF-RT regimens are well tolerated. These factors - policy, infrastructure, training, reimbursement, and perceived safety - are highly interdependent, so addressing any single barrier often requires concurrent action across multiple areas.
Conclusion
UHF RT offers a safe, effective, and efficient approach for early-stage breast cancer, with clear benefits for both patients and healthcare systems. Its broader adoption, however, depends on addressing key barriers, including infrastructure, clinician training, reimbursement models, and policy alignment. Coordinated efforts in these areas will be essential to ensure that UHF-RT can be implemented widely, maximising its clinical and economic impact.
References
- Early Breast Cancer Trialists' Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011; 378(9804):1707-16. https://doi.org/10.1016/S0140-6736(11)61629-2
- Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013; 14(11):1086-94. https://doi.org/10.1016/S1470-2045(13)70386-3
- START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008; 9(4):331-41. https://doi.org/10.1016/S1470-2045(08)70077-9
- START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008; 371(9618):1098-107. https://doi.org/10.1016/S0140-6736(08)60348-7
- Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010; 362(6):513-20. https://doi.org/10.1056/NEJMoa0906260
- Kacprowska A, Jassem J. Hypofractionated radiotherapy for early breast cancer: Review of phase III studies. Rep Pract Oncol Radiother. 2012;17(2):66-70. https://doi.org/10.1016/j.rpor.2011.10.003
- Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020; 395(10237):1613-26. https://doi.org/10.1016/S0140-6736(20)30932-6
- Meattini I, Becherini C, Boersma L, Kaidar-Person O, Marta GN, Montero A, et al. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol. 2022; 23(1):e21-31. https://doi.org/10.1016/S1470-2045(21)00539-8
- Brunt AM, Cafferty FH, Wheatley D, Sydenham MA, Kirby AM, Coles CE, et al. Patient-and clinician- assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study. Radiother Oncol. 2025; 227:110915. https://doi.org/10.1016/j.radonc.2025.110915
- Montero A, Ciérvide R, Canadillas C, Álvarez B, García-Aranda M, Alonso R, et al. Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer. Clin Transl Radiat Oncol. 2023; 41:100651. https://doi.org/10.1016/j.ctro.2023.100651
- Irabor OC, Swanson W, Shaukat F, Wirtz J, Mallum AA, Ngoma T, et al. Can the adoption of hypofractionation guidelines expand global radiotherapy access? An analysis for breast and prostate radiotherapy. JCO glob Oncol. 2020; 6:667-78. https://doi.org/10.1200/JGO.19.00261
- Glynn D, Bliss J, Brunt AM, Coles CE, Wheatley D, Haviland JS, et al. Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis. Breast Cancer Res Treat. 2022; 197(2):405-16. https://doi.org/10.1007/s10549-022-06802-1
- Mushonga M, Weiss J, Liu ZA, Nyakabau AM, Mohamad O, Tawk B, et al. Hypofractionation in breast cancer radiotherapy across World Bank income groups: Results of an international survey. JCO glob Oncol. 2023; 9:e2200127. https://doi.org/10.1200/GO.22.00127
Tinatin Alaverdashvili
Most Read Articles
-(1)-(1).jpg)
